ALLO - Allogene Therapeutics opens new manufacturing site in California

Allogene Therapeutics (NASDAQ:ALLO) unveiled its new manufacturing facility Cell Forge 1 located in Newark, California. The company said the 136K-square-foot facility will support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products for blood cancers and solid tumors. "As we prepare for our first AlloCAR T pivotal trial in mid-2022, we will draw on the capabilities of this state-of-the-art facility to meet product demand while maintaining important quality controls," said Allogene's Chief Technical Officer Alison Moore. The company said Cell Forge 1 is in proximity to its South San Francisco headquarters, allowing for close exchange among, manufacturing, research and corporate teams.

For further details see:

Allogene Therapeutics opens new manufacturing site in California